Maxim Group analyst Naz Rahman reiterated a Buy rating on Aytu BioScience (AYTU – Research Report) yesterday and set a price target of $8.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Naz Rahman has given his Buy rating due to a combination of factors including Aytu BioScience’s strong financial performance and strategic initiatives. The company reported higher-than-expected revenue and adjusted EBITDA for F3Q25, with ADHD sales showing significant growth. This indicates a positive trend in their core business operations.
Additionally, Aytu BioScience’s management has effectively controlled operating expenses and is exploring business development and acquisition opportunities to further expand beyond the ADHD franchise. The company’s consistent profitability and cash generation position it well for future growth, making it an attractive investment opportunity.
AYTU’s price has also changed dramatically for the past six months – from $1.550 to $2.590, which is a 67.10% increase.